Adial Pharmaceuticals Inc C/ Wts 31/07/2023 (To Pur Com) News

Adial Pharmaceuticals Granted Key Patent From the United States Patent and Trademark Office

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies

GlobeNewswireApr 22 08:30 ET

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial

GlobeNewswireApr 10 08:30 ET

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year

GlobeNewswireApr 2 08:30 ET

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing thera

GlobeNewswireMar 1 19:00 ET

Adial Pharmaceuticals Awarded New Patent From the United States Patent and Trademark Office

New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorderCHARLOTTESVILLE, Va., Feb.

GlobeNewswireFeb 28 09:30 ET

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on develop

AccesswireFeb 15 09:00 ET

Adial Pharmaceuticals Awarded New Patent Notice of Allowance From the United States Patent and Trademark Office

Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependenceCHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adi

GlobeNewswireFeb 13 09:15 ET

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board MemberCharlottesville, Va., Jan. 18, 2024 (GLOBE

GlobeNewswireJan 18 08:30 ET

Adial Pharmaceuticals Receives Final Reimbursement Payment From Adovate

CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing

GlobeNewswireDec 20, 2023 09:00 ET

Adial Pharmaceuticals Regains Compliance With Nasdaq Listing Requirement

CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing

GlobeNewswireNov 29, 2023 16:05 ET

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Mill

GlobeNewswireNov 14, 2023 17:02 ET

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapi

GlobeNewswireOct 24, 2023 16:30 ET

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapi

GlobeNewswireOct 20, 2023 08:00 ET

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

Allowed claims cover the detection of select genotypes for use of AD04 to treating AUD and OUD patientsCHARLOTTESVILLE, Va., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: AD

GlobeNewswireOct 19, 2023 10:30 ET

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Frost & Sullivan recognizes Adial for its best practices in precision medicine for the addiction disorders industryAdial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine

GlobeNewswireOct 18, 2023 08:00 ET

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based therapies in Alcohol Use Disorder (AUD) CHARLOTTESVILL

GlobeNewswireSep 28, 2023 07:00 ET

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developin

GlobeNewswireSep 5, 2023 08:30 ET

Adial Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

CHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing

GlobeNewswireAug 23, 2023 08:30 ET

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Reported Positive Feedback from US and EU Regulatory Meetings Sale of Purnovate Significantly Reduces Cash Burn Rate Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, In

GlobeNewswireAug 21, 2023 08:30 ET

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance With Nasdaq's Minimum Bid Price Requirement and Reduce the Public Float

Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023CHARLOTTESVILLE, Va., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Co

GlobeNewswireAug 4, 2023 08:30 ET